|
[1]DIGNAN FL,WYNN RF,HADZIC N,et al.BCSH/BSBMTguideline:diagnosis and management of veno-occlusive diseas(sinusoidal obstruction syndrome)following haematopoietic stem cell transplantation[J].Br J Haematol,2013,163(4):444-457.
|
|
[2]MOHTY M,MALARD F,ABECASSIS M,et al.Sinusoidal obstruction syndrome/veno-occlusive disease:current situation and perspectives---a position statement from the European Society for Blood and Marrow Transplantation(EBMT)[J].Bone Marrow Transplant,2015,50(6):781-789.
|
|
[3]WANG JY,GAO H.Tusanqi and hepatic sinusoidal obstruction syndrome[J].J Dig Dis,2014,15(3):105-107.
|
|
[4]WANG XX,QI XS,GUO XZ.Tusanqi-related sinusoidal obstruction syndrome in China:a systematic review of the literatures[J].Medicine(Baltimore),2015,94(23):e942.
|
|
[5]HILL KR,RHODES K,STAFFORD JL,et al.Serous hepatosis:a pathogenesisos hepatic fibrosis in Jamaican children[J].Br Med J,1953,1(4802):117-122.
|
|
[6]SHULMAN HM,McD ONALD GB,MATTHEWS D,et al.An analysis of hepatic veno-occlusive disease and centrilobular hepatic degeneration following bone marrow transplantation[J].Gastroenterology,1980,79(6):1178-1191.
|
|
[7]de LEVE L,VALLA D,GARCIATSAO G,et al.Vascular disorders of the liver[J].Hepatology,2009,49(5):1729-1764.
|
|
[8]CUTLER C,STEVENSON K,KIM H,et al.Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation[J].Blood,2008,112(12):4425-4431.
|
|
[9]RUBBIABRANDT L,TAUZIN S,BREZAULT C,et al.Gene expression profiling provides insights into pathways of oxaliplatin related sinusoidal obstruction syndrome in humans[J].Mol Cancer T-her,2011,10(4):687-696.
|
|
[10]SEIFERT C,WITTIG S,ARNDT C,et al.Heparanase polymorphisms:influence on incidence of hepatic sinusoidal obstruction syndrome in children undergoing allogeneic hematopoietic stem cell transplantation[J].J Cancer Res Clin,2014,141(5):877-885.
|
|
[11]EFRATI E,ZUCKERMAN T,BENAMI E,et al.MTHFR C677T/A1298C genotype:a possible risk factor for liver sinusoidal obstruction syndrome[J].Bone Marrow Transplant,2014,49(5):726-727.
|
|
[12]VREULS CP,OLDEDAMINK SW,KOEK GH,et al.Glutathione S-transferase M1-null genotype as risk factor for SOS in oxaliplatin-treated patients with metastatic colorectal cancer[J].Br JCancer,2013,108(3):676-680.
|
|
[13]KALLIANPUR AR,HALL LD,YADAV M,et al.The hemochromatosis C282Y allele:a risk factor for hepatic veno-occlusive disease after hematopoietic stem cell transplantation[J].Bone Marrow Transplant,2005,35(12):1155-1164.
|
|
[14]ELBAHLAWAN L,McA RTHUR J,QUASNEY MW,et al.Association of IL-1β-511 polymorphism with severe veno-occlusive disease in pediatric-matched allogeneic hematopoietic stem cell transplantation[J].J Pediatr Hematol Oncol,2012,34(3):175-179.
|
|
[15]YANG C,FRIESS SH,DEHNER LP.Hepatic mucormycosis mimicking veno-occlusive disease:report of a case and review of the literature[J].Pediatr Dev Pathol,2016,19(2):150-153.
|
|
[16]FAN CQ,CRAWFORD JM.Sinusoidal obstruction syndrome(hepatic veno-occlusive disease)[J].J Clin Exp Hepatol,2014,4(4):332-346.
|
|
[17]COPPELL J,BROWN S,PERRY D.Veno-occlusive disease:cytokines,genetics,and haemostasis[J].Blood Rev,2003,17(2):63-70.
|
|
[18]WANG XX,QI XS,GUO XZ.Sinusoidal obstruction syndrome/veno-occlusive disease:current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation(EBMT)in 2015[J].J Clin Hepatol,2015,31(5):659-664.(in Chinese)王晓晰,祁兴顺,郭晓钟.2015年欧洲骨髓移植协作组立场声明:肝窦阻塞综合征/肝小静脉闭塞症的现状和展望[J].临床肝胆病杂志,2015,31(5):659-664.
|
|
[19]CHEN Z,HUO JR.Hepatic veno-occlusive disease associated with toxicity of pyrrolizidine alkaloids in herbal preparations[J].Neth J Med,2010,68(6):252-260.
|
|
[20]de LEVE LD,ITO Y,BETHEA NW,et al.Embolization by sinusoidal lining cell obstructs the microcirculation in rat sinusoidal obstruction syndrome[J].Am J Physiol Gastrointest Liver Physiol,2003,284(6):g1045-g1052.
|
|
[21]SOON R,YEE H.Stellate cell contraction:role,regulation,and potential therapeutic target[J].Clin Liver Dis,2008,12(4):791-803.
|
|
[22]DELEVE L,WANG X,TSAI J,et al.Sinusoidal obstruction syndrome(veno-occlusive disease)in the rat is prevented by matrix metalloproteinase inhibition 1[J].Gastroenterology,2003,125(3):882-890.
|
|
[23]ROBINSON S,MANN J,VASILAKI A,et al.Pathogenesis of FOL-FOX induced sinusoidal obstruction syndrome in a murine chemotherapy model[J].J Hepatol,2013,59(2):318-326.
|
|
[24]ROBINSON S,MANN D,MANAS D,et al.The potential contribution of tumour-related factors to the development of FOLFOX-induced sinusoidal obstruction syndrome[J].Br J Cancer,2013,109(9):2396-2403.
|
|
[25]PENG T,ZHANG GY,LIU YL.Identification of Budd-Chiari syndrome,hepatic sinusoidal obstruction syndrome and hepatic cirrhosis[J].J Clin Hepatol,2011,27(10):1022-1026,1031.(in Chinese)彭涛,张国艳,刘玉兰.布-加综合征、肝血窦阻塞综合征与肝硬化的鉴别[J].临床肝胆病杂志,2011,27(10):1022-1026,1031.
|
|
[26]CHAO N.How I treat sinusoidal obstruction syndrome[J].Blood,2014,123(26):4023-4026.
|
|
[27]GAO H,RUAN JQ,CHEN J,et al.Blood pyrrole-protein adducts as a diagnostic and prognostic index in pyrrolizidine alkaloidhepatic sinusoidal obstruction syndrome[J].Drug Des Devel Ther,2015,9:4861-4868.
|
|
[28]LEE J,LEE K,SEOL M,et al.Plasminogen activator inhibitor-1is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adults conditioned with busulphan and cyclophosphamide[J].Br J Haematol,2002,118(4):1087-1094.
|
|
[29]LEE JH.Biomarkers for hepatic sinusoidal obstruction syndrome after hematopoietic cell transplantation[J].Blood Res,2015,50(3):123-125.
|
|
[30]SHAO H,CHEN HZ,ZHU JS,et al.Computed tomography findings of hepatic veno-occlusive disease caused by Sedum aizoon with histopathological correlation[J].Braz J Med Biol Res,2015,48(12):1145-1150.
|
|
[31]DUMONT CH,LAMBERT M,van BEERS BE.MR imaging finding in a patient with hepatic veno-occlusive disease[J].Acta Gastroenterol Bels,2004,67(2):236-238.
|
|
[32]APPERLEY J,CARRERAS E,GLUCKMAN T,et al.The EBMT-ESH handbook on haemo-poietic stem cell transplantation[EB/OL].[2015-5-13].http://ebmtonline.forumservice.net/media/11/tex/content_alt/EBMT_Handbook 2012_CHAP11.pdf.
|
|
[33]CHENG JY,WANG TL,ZHAO XY,et al.Analysis of liver specimen quality using 280 specimens obtained by routine puncture biopsy[J].Chin J Hepatol,2014,22(3):231-232.(in Chinese)程捷尧,王泰龄,赵新颜,等.280例肝穿刺标本质量调查分析[J].中华肝脏病杂志,2014,22(3):231-232.
|
|
[34]CARRERAS E.How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation[J].Br J Haematol,2015,168(4):481-491.
|
|
[35]YOON JH,MIN WS,KIM HJ,et al.Experiences of t-PA use in moderate-to-severe hepatic veno-occlusive disease after hematopoietic SCT:is it still reasonable to use t-PA?[J].Bone Marrow Transplant,2013,48(12):1562-1568.
|
|
[36]IBRAHIM R,PERES E,DANSEY R,et al.Anti-thrombinⅢin the management of hematopoietic stem-cell transplantation-associated toxicity[J].Ann Pharmacother,2004,38(6):1053-1059.
|
|
[37]HAUSSMANN U,FISCHER J,EBER S,et al.Hepatic veno-occlusive disease in pediatric stem cell transplantation:impact of pre-emptive antithrombinⅢreplacement and combined antithrombinⅢ/defibrotide therapy[J].Haematologica,2006,91(6):795-800.
|
|
[38]RICHARDSON PG,HO VT,GIRALT S,et al.Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease[J].Ther Adv Hematol,2012,3(4):253-265.
|
|
[39]RICHARDSON PG,SOIFFER RJ,ANTIN JH,et al.Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation:a multicenter,randomized,dose-finding trial[J].Biol Blood Marrow Transplant,2010,16(7):1005-1017.
|
|
[40]RICHARDSON P,MURAKAMI C,JIN Z,et al.Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure:response without significant toxicity in a high-risk population and factors predictive of outcome[J].Blood,2002,100(13):4337-4343.
|
|
[41]CORBACIOGLU S,CESARO S,FARACI M,et al.Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation:an open-label,phase 3,randomised controlled trial[J].Lancet,2012,379(9823):1301-1309.
|
|
[42]HELMY A.Review article:updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome[J].Aliment Pharm T-her,2006,23(1):11-25.
|
DownLoad: